RESUMEN
BACKGROUND: The frequency, mortality, and morbidity of very low birth weight (VLBW) infants with congenital heart disease (CHD) in Asian countries are limited. In addition, little is known about the risk factors of death in these infants. METHODS: A retrospective, multicenter cohort study was conducted. VLBW infants with CHD born between 2006 and 2010, and followed to 5â¯years of age, were included in the analysis. Multiple logistic regression analysis was performed to identify the risk factors of death. RESULTS: Among 3247 VLBW infants, 126 various CHDs (3.9â¯%) were identified. The most common lesions were ventricular septal defect, tetralogy of Fallot (TOF), and coarctation of the aorta/interrupted aortic arch, in that order. The proportions of left-sided and right-sided outflow obstruction (TOF, pulmonary stenosis) were 15.1â¯% and 15.9â¯%, respectively. Trisomy 18 and trisomy 13 were present in 32 (25.4â¯%) of 126 VLBW infants with CHD. Nine patients were lost to follow-up. Overall, 45 patients (35.7â¯%) died up to 5â¯years of age. Serious CHD [odds ratio (OR), 19.2; 95â¯% confidential interval (CI), 3.94-93.11; pâ¯<â¯0.0001], sepsis (OR, 42.3; 95â¯% CI, 5.39-332.22; pâ¯<â¯0.0001), chromosomal /named anomalies (OR, 7.50; 95%CI, 2.09-26.94; pâ¯=â¯0.001), and no-invasive treatments (OR, 9.89; 95%CI, 2.28-42.91; pâ¯=â¯0.001) were associated with death. On excluding chromosomal anomalies, twelve of 71 patients (16.9â¯%) died, and only sepsis (OR, 35.5, 95%CI, 2.63-477.1; pâ¯=â¯0.0008) was an independent risk factor. CONCLUSIONS: Trisomy 18 and trisomy 13 of chromosomal anomalies are frequently associated with VLBW infants with CHD. The mortality of VLBW infants with CHD is high, even when chromosomal anomalies are excluded. Sepsis has a significant impact on death in VLBW infants with CHD.
Asunto(s)
Cardiopatías Congénitas , Sepsis , Tetralogía de Fallot , Estudios de Cohortes , Cardiopatías Congénitas/complicaciones , Humanos , Lactante , Recién Nacido , Recién Nacido de muy Bajo Peso , Japón/epidemiología , Estudios Retrospectivos , Síndrome de la Trisomía 13/complicaciones , Síndrome de la Trisomía 18/complicacionesAsunto(s)
Protección Radiológica , Niño , Humanos , Japón , Dosis de Radiación , Radiografía , Tecnología RadiológicaRESUMEN
BACKGROUND Pfeiffer syndrome (PS) is a fibroblast growth factor receptor (FGFR)-associated craniosynostosis syndrome, characterized by abnormally broad and medially deviated thumbs and great toes. Tracheal cartilage sleeve (TCS) is associated with several FGFR-associated craniosynostosis syndromes, including PS. TCS is an airway malformation in which the tracheal cartilage rings fuse with each other to form a sleeve of cartilage. CASE REPORT The patient was a 4-year-old girl with PS, TCS, and abnormal hyperplasia of non-fused intrapulmonary cartilages. The patient showed cranial dysplasia on prenatal ultrasonography. At birth, a cloverleaf skull in association with hydrocephalus and digital malformations was apparent. These findings were consistent with PS type 2. The diagnosis of PS type 2 was confirmed from a genetic test detecting a FGFR2 mutation (Y340C). During the clinical course, she underwent several surgeries, including ventriculoperitoneal shunts, sequential cranioplasty surgeries, and tracheotomy due to upper airway abnormalities. At 4 years old, she died of multiple organ failure following aspiration pneumonia. The autopsy revealed that the tracheal cartilages had fused with each other, resulting in a condition called TCS, in which the cartilage rings and tracheal ligaments were absent. The lungs were poorly aerated, and the dilated bronchi had thickened walls surrounded by many cartilage fragments, mainly at the hilum. These cartilages tended to overlap at both ends, did not fuse, and were greatly altered in size and shape. CONCLUSIONS We report the results of autopsy for PS with the first histopathological findings for the lungs and other visceral organs.
Asunto(s)
Acrocefalosindactilia , Craneosinostosis , Acrocefalosindactilia/patología , Autopsia , Bronquios , Cartílago/patología , Preescolar , Femenino , Humanos , Hiperplasia/patología , Recién Nacido , Fenotipo , Embarazo , Receptor Tipo 2 de Factor de Crecimiento de Fibroblastos/genética , SíndromeRESUMEN
Syndromic craniosynostoses usually occur as single gene disorders. In this study, we analyzed FGFR1-3 genes in four patients with Crouzon syndrome (CS), four patients with Pfeiffer syndrome type 2 (PS-2), one patient with Jackson-Weiss syndrome (JWS), and two patients (sisters) with Muenke syndrome (MS). FGFR2 and FGFR3 mutations were identified in 10 of the 11 patients. Notably, we found a novel FGFR2 p.Asn549Thr mutation in a patient with CS, and a novel FGFR2 p.Ser347Cys mutation in a patient with JWS (thus, this patient was turned out to have an FGFR2-related PS-variant). We also identified an FGFR2 p.Ser252Leu mutation in a phenotypically normal father of a daughter with CS, and an FGFR3 p.Pro250Arg mutation in a mildly macrocephalic father of sisters with MS. These findings, together with previous data, imply that the same FGFR2 mutations can be associated with a wide range of phenotypes including clinically different forms of syndromic craniosynostosis and apparently normal phenotype, depending on other (epi)genetic and environmental factors. Thus, genetic studies are recommended not only for obviously affected individuals but also for family members with apparently normal phenotype or non-specific subtle abnormal phenotype, to allow for pertinent genetic counseling. © 2016 Wiley Periodicals, Inc.
Asunto(s)
Pueblo Asiatico/genética , Craneosinostosis/diagnóstico , Craneosinostosis/genética , Mutación , Receptor Tipo 1 de Factor de Crecimiento de Fibroblastos/genética , Receptor Tipo 2 de Factor de Crecimiento de Fibroblastos/genética , Receptor Tipo 3 de Factor de Crecimiento de Fibroblastos/genética , Alelos , Sustitución de Aminoácidos , Análisis Mutacional de ADN , Diagnóstico por Imagen/métodos , Facies , Femenino , Estudios de Asociación Genética , Genotipo , Humanos , Lactante , Recién Nacido , Japón , Masculino , Fenotipo , SíndromeRESUMEN
Our study was involved with entrance surface dose reduction and irradiation field by the filter use of PCI, and insertion in place of an effective compensating filter to maximize entrance surface dose reduction, which we verified. The radiation dosimetry put a 6cc ion chamber on the back side of the thorax phantom, and changed the filter of the four corners (a: upper left, b: upper right, c: lower right, d: lower left) of the monitor confirmed with fluoroscopy [(0) no filter, (1) one filter, (2) two filters]. The angle of C arm was assumed to be eight directions and 0 degrees adopted by this hospital. It was compared with a corrective rate of which one was no filter. Next, the presence of filter and irradiation field overlaps on the area in monitor in the angle of C arm was verified by this hospital's classic example. As for corrective rate, (1) becomes 0.41 and (2) become 0.25 at fluoroscopy, (1) becomes 0.26 and (2) become 0.16 at exposure. Irradiation field overlaps on the area (+) compensating filter (-) was many with d of RAO/CAU, a of RAO and c of CAU at left CAG, c of LAO at right CAG, b of LAO/CRA (left CAG), b of CRA (right CAG) and a and d of RAO (right CAG) at both CAG. Irradiation field overlaps on the area (+) compensating filter (+) was many with b of CRA at left CAG, a of LAO/CRA at right CAG, b of CRA (left CAG) and b of RAO (right CAG) at both CAG. When the compensating filter is used the entrance surface dose reduction effect was great. If automatic exposure control protects the part of irradiation field overlaps on the area in the range without operating excessively, the radiological risk can be reduced, and it is conceivable as useful clinical setting.
Asunto(s)
Angioplastia Coronaria con Balón , Filtración , Dosis de Radiación , Protección Radiológica/métodos , Piel/efectos de la radiación , Humanos , Conducta de Reducción del RiesgoAsunto(s)
Anemia Hemolítica/complicaciones , Hemólisis , Enfermedades del Prematuro/etiología , Recien Nacido Prematuro , Metahemoglobinemia/etiología , Anemia Hemolítica/diagnóstico , Diagnóstico Diferencial , Estudios de Seguimiento , Humanos , Recién Nacido , Enfermedades del Prematuro/diagnóstico , Recién Nacido de muy Bajo Peso , Masculino , Metahemoglobinemia/diagnósticoRESUMEN
OBJECTIVE AND DESIGN: We investigated the involvement of heme oxygenase (HO)-1 in the anti-allergic action of quercetin against degranulation of rat basophilic leukemia (RBL-2H3) cells, rat peritoneal mast cells, and mouse bone marrow-derived mast cells. METHODS: The strength of allergic reaction was evaluated by the extent of degranulation in mast cells sensitized with various stimulants. The levels of HO-1, HO-2, and nuclear factor erythroid 2-related factor 2 (Nrf2) expressions were determined by quantitative RT-PCR, western blotting, or immunocytochemistry. RESULTS: Heme oxygenase activity was upregulated after short exposure to quercetin, followed by the induction of HO-1 expression after long exposure to quercetin. The inhibition of degranulation by quercetin was reversed using tin protoporphyrin IX (SnPP), an HO-1 inhibitor. HO-1 metabolites, bilirubin and CO, led to inhibit degranulation, and quercetin translocated Nrf2 from cytoplasm into nucleus in RBL-2H3 cells. CONCLUSION: These results strongly suggest that quercetin exerted anti-allergic actions via activation of Nrf2-HO-1 pathway.
Asunto(s)
Antioxidantes/farmacología , Degranulación de la Célula/efectos de los fármacos , Hemo-Oxigenasa 1/metabolismo , Hipersensibilidad/prevención & control , Mastocitos/metabolismo , Quercetina/farmacología , Animales , Bilirrubina/farmacología , Monóxido de Carbono/farmacología , Células Cultivadas , Modelos Animales de Enfermedad , Inhibidores Enzimáticos/farmacología , Hemo Oxigenasa (Desciclizante)/metabolismo , Hemo-Oxigenasa 1/antagonistas & inhibidores , Hipersensibilidad/metabolismo , Hipersensibilidad/patología , Leucemia Basofílica Aguda/metabolismo , Leucemia Basofílica Aguda/patología , Mastocitos/efectos de los fármacos , Mastocitos/patología , Metaloporfirinas/farmacología , Ratones , Ratones Endogámicos BALB C , Factor 2 Relacionado con NF-E2/metabolismo , Protoporfirinas/farmacología , Ratas , Ratas WistarRESUMEN
Kaempferol is one of the most commonly found dietary flavonoids. The exposure to kaempferol is known to inhibit degranulation from mast cells, but the inhibitory mechanism of degranulation has not been clarified yet. In this study, we investigated the involvement of heme oxygenase (HO)-1 in the anti-allergic action of kaempferol against degranulation in rat basophilic leukemia (RBL-2H3) cells. Our results demonstrate upregulation of HO enzymatic activity after short (15 min) exposure to kaempferol, followed by the induction of HO-1 expression in protein. The involvement of HO-1 in the kaempferol-induced inhibition of degranulation was confirmed using tin protoporphyrin IX (SnPP), a HO-1 inhibitor. These findings strongly suggest that kaempferol exerts anti-allergic actions via activation of the HO-1.